In the same study, the clinical benefit rate was greater in patients with PD-L1−negative tumors than PD-L1−positive tumors (68.2% vs 42.9%), although the difference did not reach statistical significance ( P = 0.095) 66 .
1
0.0950
0.0950
In the same study, the clinical benefit rate was greater in patients with PD-L1−negative tumors than PD-L1−positive tumors (68.2% vs 42.9%), although the difference did not reach statistical significance ( P = 0.095) 66 .